Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Palliative treatment of waldenström’s macroglobulinemia

Jorge Castillo • 13 Sep 2019
IMW 2019
Multiple Myeloma Rare Diseases Waldenström’s Macroglobulinemia Bendamustine Bortezomib Carfilzomib Cyclophosphamide Ibrutinib Ixazomib Rituximab

Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the options for palliative treatment in symptomatic waldenström’s macroglobulinemia (WM) patients. Interview recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Jorge Castillo

2:22
Real-world outcomes following dose reduction of first-line ibrutinib in patients with WM
Jorge Castillo • 10 Dec 2023
2:27
Acalabrutinib plus rituximab for treating anti-MAG mediated IgM peripheral neuropathy in WM
Jorge Castillo • 10 Dec 2023
3:03
Outcomes following venetoclax monotherapy in patients with R/R WM in the real-world setting
Jorge Castillo • 10 Dec 2023
3:32
Research updates in WM from ASH 2023
Jorge Castillo • 10 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals